Reported at the Presenting here at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis(ECTRIMS)
Reported in this medscape article...
http://www.medscape.com/viewarticle/730736
1. The test could be avaiable in the market as early as January.(now its a trial)
2.It has been evaluated in 5,000 patients, internationally in AFFIRM,TYGRIS, STRATISFY-I
3. PML is lower in anti-JCV antibody negative than positive
4. the JCV anti body positive prevelance was between 48-61% across all the trials
5. PML incident of people who have used Tysabri for at least 18 months is 1.63 per 1,000
6.The prevalence of anti JCV antibodies is not affected by prior immunsuppresant use
7. Positive JCV anti bodies was less common in woman than men but the likely hood of testing positive increased with age.
8. The false negative rate is 2.5% & spontaneous seroconversion rate of negative testers is 2% suggesting periodic testing for JCV anti bodies of people using tysabri---(I'm very excited to read this, as you can look at a previous post I wrote that my doc had no confidence in 1 test as a person could pick yup the HCV anytimme after the blood test was done--I just like it that my doc;s opinions are 4expressed in their final analysis. My doc is sharp & that makes me feel better.)
9. 4 of 1094 people who had Tysabri treatment holiday died of PML, so it calls into question the advantages of a treatment holiday. 3 of the 4 hasd previously used an immunesuppressive which increases the risk of PML
My note: Past use of an immunesuppressive like novatrone, cellcept is not the immunomodulatars like betaseron,avonnex,rebif & past use of an immunosuppressive increases PML risk but does not inrease the likelyhood JCV antibody positive test result.
10. Currently 68 patients using Tysabri have gotten PML and of those 14 died.
Reported in this medscape article...
http://www.medscape.com/viewarticle/730736
1. The test could be avaiable in the market as early as January.(now its a trial)
2.It has been evaluated in 5,000 patients, internationally in AFFIRM,TYGRIS, STRATISFY-I
3. PML is lower in anti-JCV antibody negative than positive
4. the JCV anti body positive prevelance was between 48-61% across all the trials
5. PML incident of people who have used Tysabri for at least 18 months is 1.63 per 1,000
6.The prevalence of anti JCV antibodies is not affected by prior immunsuppresant use
7. Positive JCV anti bodies was less common in woman than men but the likely hood of testing positive increased with age.
8. The false negative rate is 2.5% & spontaneous seroconversion rate of negative testers is 2% suggesting periodic testing for JCV anti bodies of people using tysabri---(I'm very excited to read this, as you can look at a previous post I wrote that my doc had no confidence in 1 test as a person could pick yup the HCV anytimme after the blood test was done--I just like it that my doc;s opinions are 4expressed in their final analysis. My doc is sharp & that makes me feel better.)
9. 4 of 1094 people who had Tysabri treatment holiday died of PML, so it calls into question the advantages of a treatment holiday. 3 of the 4 hasd previously used an immunesuppressive which increases the risk of PML
My note: Past use of an immunesuppressive like novatrone, cellcept is not the immunomodulatars like betaseron,avonnex,rebif & past use of an immunosuppressive increases PML risk but does not inrease the likelyhood JCV antibody positive test result.
10. Currently 68 patients using Tysabri have gotten PML and of those 14 died.
Comment